CANY
AKBA icon

Caxton Associates (New York)’s Akebia Therapeutics AKBA Stock Holding History

Caxton Associates (New York)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,126
Closed -$178K – 304
2020
Q2 		$178K Buy
+13,126
New +$136K 0.02% 388
2017
Q4 		– Sell
-12,500
Closed -$246K – 336
2017
Q3 		$246K Buy
+12,500
New +$192K 0.01% 459

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s AKBA Position: Q3 2020 in Review

Caxton Associates (New York) sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 13,126 shares — an estimated $178K sold.

Caxton Associates (New York) first reported a position in AKBA in Q3 2017 and held it in 2 quarters. The position peaked at $246K in Q3 2017. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Caxton Associates (New York) reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 13,126 Akebia Therapeutics shares in Q3 2020, an estimated $178K.
  • Caxton Associates (New York) first reported a position in Akebia Therapeutics in Q3 2017 and held it in 2 quarters.
  • Caxton Associates (New York)'s Akebia Therapeutics position peaked at $246K in Q3 2017.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Caxton Associates (New York)'s 13F filing for Q3 2020, filed 16 Nov 2020.